Johnson & Johnson (J&J) Chief Scientific Officer, Dr. Paul Stoffels said on a call with media that the giant pharma needs to enlist 60,000 adult participants in its Phase 3 trials in the U.S. as it begins today, CNN reported.
Is it Better Than the Other Potential Vaccines?
Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, developed the vaccine candidate per CNN.
The vaccine prototype may have a substantial advantage over some of its competitors, experts said, according to the New York Times.
In particular, the J&J candidate does not need to be stored in subzero temperatures.
Furthermore, it may require just one dosage instead of two.
The single-dose “should expedite results,” said Stoffels.
“We’re convinced” it could be “very efficacious,” added Stoffels.
Unpublished But Very Encouraging Early Phase of Trials
The healthcare company started its human trials in July in the US and Belgium, Business Insider reported.
The results, however, have not been published from those studies.
While it may be true, Dr. Stoffels said the results were positive and promising.
Dr. Stoffels said, J&J will soon publish the data online from the trial’s earlier phase, per the New York Times.
Where Will the Vaccine Candidate be Tested?
J&J will carry out the trials in nearly 215 sites including Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa, and the United States.
Dr. Stoffels said the healthcare company pledged to test the vaccine in children subsequently after it has proven safe for adults.
Also, J&J intends to run a separate Phase 3 trial, in collaboration with the British government, per CNN.
The separate Phase 3 trial will scrutinize the effectiveness of two doses.
Time is of the Essence
Dr. Judith Feinberg thinks it would be fabulous to have a single dose vaccine, per the New York Times.
Dr. Feinberg, though not involved in the study, is the vice chairwoman for research in medicine at West Virginia University.
If the vaccine is proven effective on the Phase 3 trial, it could speed up curbing the pandemic, Dr. Feinberg added.
The pressing “issue is time” and we have to administer the vaccine to “a lot of people quickly,” she said.
Dr. Stoffels spoke at a news conference Tuesday.
According to him, the vaccine’s safety and effectiveness can be determined by J&J by the end of the year.